Developer docs
API playgroundTry for free, no card

Search company profiles

Ferozsons Laboratories

Full company profile

uuid0024c9r

Namestring
Ferozsons Laboratories
Legal namestring
Ferozsons Laboratories Limited
Company typeenum
Public
Founded yearint
1954
Descriptiontext

Ferozsons Laboratories Limited is a Pakistan-headquartered, publicly listed pharmaceutical company (PSX ticker FEROZ) founded in 1954 with manufacturing operations beginning in 1956. The company produces and markets more than 140 branded generic pharmaceutical products across 12+ therapeutic areas, including cardiology, hepatology, gastroenterology, oncology, diabetes, antivirals, and antibiotics, manufactured at a cGMP-compliant facility in Nowshera (Khyber Pakhtunkhwa) certified to ISO, ICH, WHO, and PIC/S standards. Revenue is generated through four streams: domestic pharmaceutical sales, international exports to 30+ countries across Asia, Africa, Europe, South America, and Central America, contract manufacturing for global pharmaceutical companies (historically including Boots UK, Grunenthal, and Procter & Gamble), and medical-device distribution through partnerships with Boston Scientific, Nihon Kohden, GE Healthcare, and Butterfly Network.

The business model combines first-party branded generics with royalty-free voluntary licensing for breakthrough therapies from Gilead Sciences, including Sovaldi (sofosbuvir for hepatitis C), Remedia (remdesivir for COVID-19), and Yeztugo (lenacapavir for HIV PrEP), the last of which covers 120 high-incidence resource-limited countries. Biopharmaceutical capability is housed in BF Biosciences Limited, a joint venture with Argentina's Bagó Group established in 2006, which operates Pakistan's only cGMP-compliant biotech facility and was separately listed on the Pakistan Stock Exchange in 2024. Through this subsidiary, Ferozsons launched Sematide (semaglutide) in 2024 and Zeptide (tirzepatide) in 2025, marking entry into the GLP-1 therapeutic class for diabetes and obesity.

FY2025 reported net sales of PKR 13.858 billion (approximately USD 45-50 million), up 9% year-over-year, with net profit of PKR 528.243 million and gross margin of 41.27%, following a margin-compressed 2023. The company is led by CEO Osman Khalid Waheed, with Amna Piracha Khan as Chairperson of the Board, and operates from corporate headquarters in Lahore with a registered office in Rawalpindi and the Nowshera manufacturing site.

Short descriptiontext

Ferozsons Laboratories is a publicly listed Pakistani pharmaceutical company (PSX: FEROZ) that manufactures and distributes 140+ branded generics, in-licensed breakthrough therapies from Gilead Sciences, and advanced medical devices through global partnerships, serving patients in Pakistan and 30+ export markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLahore, Pakistan
HQ citystring
Lahore
HQ countrystring
Pakistan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines, biotechnology products, medical device distribution, hepatitis treatments
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Sales (Domestic)
TypeOne Time License
Description

Sale of branded generic pharmaceutical products across multiple therapeutic areas including cardiology, hepatology, gastroenterology, oncology, antivirals, antibiotics, and diabetes treatments. Net sales reached Rs.13,857.967 million in FY2025 with gross margin of 41.27%.

brecorder.com
2Licensed Products (Gilead Partnership)
TypeLicensing Royalties
Description

Manufacturing and distribution of in-licensed products from Gilead Sciences including Sovaldi (sofosbuvir) for Hepatitis C, Remedia (remdesivir) for COVID-19, and Yeztugo (lenacapavir) for HIV prevention. Royalty-free voluntary licensing for 120 high-incidence countries.

fiercepharma.com
3Contract Manufacturing
TypeOne Time License
Description

cGMP-compliant manufacturing services for international pharmaceutical companies. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble (Vicks VapoRub).

ferozsons-labs.com
4Medical Devices Distribution
TypeOne Time License
Description

Distribution of advanced medical technologies including Boston Scientific interventional devices (cardiology, GI endoscopy, oncology, urology), Nihon Kohden patient monitoring and diagnostic systems, and Butterfly Network handheld ultrasound technology.

ferozsons-labs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Remedia
Description

Remdesivir product launched for COVID-19 treatment under voluntary licensing partnership with Gilead

ferozsons-labs.com
+3 more records
Core offering1 text field

Ferozsons Laboratories is a pharmaceutical manufacturer that develops, produces, and sells more than 140 branded generic medicines across therapeutic areas including oncology, cardiology, hepatology, gastroenterology, antidiabetics, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. The company also distributes advanced medical devices through global partnerships and operates cGMP-compliant contract manufacturing services for international pharmaceutical clients. Its subsidiary BF Biosciences manufactures biopharmaceuticals such as Sematide and Zeptide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 250,000 hepatitis C patients cured nationwide through Sovaldi access program
+3 more records
Product overview1 text field

Ferozsons Laboratories Limited operates as a patient-centric pharmaceutical company offering a broad portfolio of more than 140 pharmaceutical products across 12+ therapeutic areas (oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief). The company operates through two divisions: Pharmaceuticals (branded generics and in-licensed products) and Medical Technologies (distribution of advanced medical devices through global partnerships). Key pharmaceutical brands include Sovaldi (Hepatitis C), Remedia (COVID-19), and DiaresQ (childhood diarrhea). Subsidiary BF Biosciences Limited focuses on biopharmaceuticals including Zeptide (Tirzepatide) and Sematide (Semaglutide) for diabetes and obesity. Medical Technologies division distributes Boston Scientific interventional devices, Nihon Kohden diagnostic/monitoring systems, and Butterfly Network handheld ultrasound devices. The company also offers cGMP-compliant contract manufacturing services.

Product and service11 records
1Zeptide (Tirzepatide)
CategoryBiopharmaceutical - Diabetes/Obesity
Description

An innovative tirzepatide treatment for Type 2 diabetes and obesity, manufactured and launched in Pakistan by BF Biosciences Limited (Ferozsons' biopharmaceutical joint venture with Bagó Group of Argentina). Targeted at patients needing advanced metabolic disease therapy.

2Sematide (Semaglutide)
CategoryBiopharmaceutical - Diabetes
Description

Pakistan's first locally manufactured GLP-1 semaglutide therapy for diabetes, produced by BF Biosciences Limited. Targeted at patients requiring advanced GLP-1 therapy in Pakistan.

3Remedia (Remdesivir)
CategoryAntiviral - COVID-19
Description

Remdesivir COVID-19 treatment manufactured under voluntary licensing partnership with Gilead Sciences for severe COVID-19 in hospitalized patients, also exported internationally.

4Sovaldi (sofosbuvir)
CategoryAntiviral - Hepatitis C
Description

Sofosbuvir breakthrough direct-acting antiviral therapy for Hepatitis C introduced in Pakistan under a dedicated patient access program through partnership with Gilead Sciences.

5DiaresQ
CategoryNutritional - Pediatric Diarrhea
Description

Innovative nutritional product for childhood diarrhea, exclusively marketed in Pakistan through partnership with PanTheryx Inc., USA. Targeted at pediatric patients and caregivers.

6Branded Generic Pharmaceutical Portfolio (140+ products)
CategoryPharmaceutical - Branded Generics
Description

Broad portfolio of more than 140 branded generic pharmaceutical products covering oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. Targeted at healthcare providers and patients across Pakistan and 30+ export markets.

7Farapulse PFA System
CategoryMedical Device - Interventional Cardiology
Description

Pulsed Field Ablation system developed by Boston Scientific for treatment of atrial fibrillation, introduced in Pakistan through Ferozsons' distribution partnership. Targeted at cardiology departments and electrophysiologists treating atrial fibrillation.

8Boston Scientific Medical Devices Distribution
CategoryMedical Device Distribution Portfolio
Description

Authorized distribution in Pakistan of Boston Scientific interventional medical devices across cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Targeted at Pakistani healthcare providers and hospitals.

9Nihon Kohden Medical Technologies Distribution
CategoryMedical Device Distribution Portfolio
Description

Authorized distribution in Pakistan of Nihon Kohden advanced diagnostic and patient monitoring systems including patient monitoring, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring. Targeted at Pakistani hospitals.

10Butterfly Network Handheld Ultrasound Distribution
CategoryMedical Device Distribution Portfolio
Description

Authorized distribution in Pakistan of Butterfly Network handheld ultrasound technology and AI-enabled digital medical imaging solutions with applications in emergency medicine, critical care, obstetrics, and primary care. Targeted at Pakistani healthcare providers.

11Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

cGMP-compliant pharmaceutical manufacturing services with capacity for tablets (550M annually), capsules (222M), dry suspensions (2.5M bottles), ointments/creams (11M tubes), sachets (11M), ampoules, vials, pre-filled syringes, and lyophilized products. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble. Targeted at international pharmaceutical and consumer health companies outsourcing production.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Nihon Kohden
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Distribution partnership for advanced diagnostic and patient monitoring systems. Technologies include patient monitoring systems, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring technologies for hospitals and healthcare facilities across Pakistan.

ferozsons-labs.com
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Exclusive marketing partnership for DiaresQ, an innovative nutritional product for childhood diarrhea. Product recognized in Innovations 2030 Countdown Report by PATH, USAID, and NORAD.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-01-01
Description

Channel partnership for marketing and sale of value-segment medical devices in Pakistan, expanding medical technology portfolio beyond pharmaceutical products.

4BioGaia
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2012-01-01
Description

Partnership to introduce world's leading premium Swedish probiotics in Pakistan, expanding product portfolio in nutritional and digestive health category.

ferozsons-labs.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2008-01-01
Description

Authorized distributor in Pakistan for Boston Scientific medical devices since 2008. Partnership covers advanced interventional technologies in cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Ferozsons introduced Pakistan's first public-sector Pulsed Field Ablation programme at PIMS using the Farapulse PFA System.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2006-01-01
Description

Joint venture established in 2006 to create BF Biosciences Limited, Pakistan's first biopharmaceutical company. cGMP-compliant biotechnology facility dedicated to manufacture of biological products. BF Biosciences successfully listed on PSX in 2024 following IPO. Strategic partnership also includes import and marketing of biological products in oncology and liver disease.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2002-01-01
Description

Strategic partnership for import and marketing of biological products in oncology and liver disease from Germany.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Royalty-free voluntary licensing partnership for manufacture and distribution of lenacapavir (HIV PrEP), sofosbuvir/Sovaldi (Hepatitis C), and remdesivir/Remedia (COVID-19) in 120 high-incidence resource-limited countries. Ferozsons is one of six generic partners including Dr. Reddy's, Emcure, Eva Pharma, Hetero, and Mylan. The partnership enabled introduction of breakthrough therapies in Pakistan including first direct-acting antiviral for Hepatitis C.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor in Pakistan for Butterfly Network handheld ultrasound technology and digital medical imaging. Enables introduction of AI-enabled portable ultrasound solutions to healthcare providers across Pakistan with applications in emergency medicine, critical care, obstetrics, and primary care.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Indian-headquartered global generic and biopharmaceutical company with a similar voluntary licensing-led model for breakthrough antivirals (also a Gilead licensee). Comparable in licensed generics strategy, biopharma ambitions, and emerging markets export focus.

TypeDirect peer
Description

Listed Pakistani pharmaceutical company offering branded generics and licensed products across similar therapeutic categories. Directly comparable in business model, regulatory standing, and Pakistan Stock Exchange listing.

TypeBroad incumbent
Description

Multinational pharmaceutical incumbent with established Pakistan presence across branded generics and nutrition. Comparable as a competitor in the same therapeutic categories, though with broader global portfolio backing.

TypeEmerging player
Description

Indian-headquartered global generics manufacturer and one of the six Gilead voluntary licensees for Sovaldi, Remdesivir, and lenacapavir. Directly comparable in licensed antiviral manufacturing model and emerging markets supply footprint.

TypeBroad incumbent
Description

Multinational pharmaceutical and consumer health incumbent with Pakistan operations spanning cardiology, women's health, and specialty. Comparable as an established incumbent with overlapping product categories.

TypeDirect peer
Description

Karachi-based Pakistani pharmaceutical manufacturer with a comparable branded generics and licensing-led business model. Closely comparable in product breadth, domestic sales motion, and therapeutic area coverage.

TypeDirect peer
Description

Pakistani pharmaceutical company operating in branded generics across multiple therapeutic areas including cardiology and gastroenterology. Directly comparable mid-sized domestic peer.

TypeDirect peer
Description

One of Pakistan's largest domestic pharmaceutical manufacturers with a broad branded generics portfolio across multiple therapeutic areas. Highly comparable in product mix, domestic market positioning, and export ambitions to Ferozsons.

TypeRegional player
Description

Pakistani pharmaceutical manufacturer with broad branded generics portfolio. Comparable mid-cap domestic peer with overlapping therapeutic categories and similar Pakistan PSX listing structure.

TypeBroad incumbent
Description

Listed Pakistani subsidiary of GSK offering vaccines, specialty, and general medicines. Comparable as a broad incumbent competing for the same prescriber base and therapeutic franchises.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ferozsons Laboratories

Pharmaceutical Manufacturingferozsons-labs.com

Ferozsons Laboratories is a publicly listed Pakistani pharmaceutical company (PSX: FEROZ) that manufactures and distributes 140+ branded generics, in-licensed breakthrough therapies from Gilead Sciences, and advanced medical devices through global partnerships, serving patients in Pakistan and 30+ export markets.

What Ferozsons Laboratories does

Ferozsons Laboratories Limited is a Pakistan-headquartered, publicly listed pharmaceutical company (PSX ticker FEROZ) founded in 1954 with manufacturing operations beginning in 1956. The company produces and markets more than 140 branded generic pharmaceutical products across 12+ therapeutic areas, including cardiology, hepatology, gastroenterology, oncology, diabetes, antivirals, and antibiotics, manufactured at a cGMP-compliant facility in Nowshera (Khyber Pakhtunkhwa) certified to ISO, ICH, WHO, and PIC/S standards. Revenue is generated through four streams: domestic pharmaceutical sales, international exports to 30+ countries across Asia, Africa, Europe, South America, and Central America, contract manufacturing for global pharmaceutical companies (historically including Boots UK, Grunenthal, and Procter & Gamble), and medical-device distribution through partnerships with Boston Scientific, Nihon Kohden, GE Healthcare, and Butterfly Network.

The business model combines first-party branded generics with royalty-free voluntary licensing for breakthrough therapies from Gilead Sciences, including Sovaldi (sofosbuvir for hepatitis C), Remedia (remdesivir for COVID-19), and Yeztugo (lenacapavir for HIV PrEP), the last of which covers 120 high-incidence resource-limited countries. Biopharmaceutical capability is housed in BF Biosciences Limited, a joint venture with Argentina's Bagó Group established in 2006, which operates Pakistan's only cGMP-compliant biotech facility and was separately listed on the Pakistan Stock Exchange in 2024. Through this subsidiary, Ferozsons launched Sematide (semaglutide) in 2024 and Zeptide (tirzepatide) in 2025, marking entry into the GLP-1 therapeutic class for diabetes and obesity.

FY2025 reported net sales of PKR 13.858 billion (approximately USD 45-50 million), up 9% year-over-year, with net profit of PKR 528.243 million and gross margin of 41.27%, following a margin-compressed 2023. The company is led by CEO Osman Khalid Waheed, with Amna Piracha Khan as Chairperson of the Board, and operates from corporate headquarters in Lahore with a registered office in Rawalpindi and the Nowshera manufacturing site.

Ferozsons Laboratories firmographics

Firmographics
Name
Ferozsons Laboratories
Legal name
Ferozsons Laboratories Limited
Website
https://ferozsons-labs.com
Company type
Public
Founded year
1954
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Ferozsons Laboratories is a publicly listed Pakistani pharmaceutical company (PSX: FEROZ) that manufactures and distributes 140+ branded generics, in-licensed breakthrough therapies from Gilead Sciences, and advanced medical devices through global partnerships, serving patients in Pakistan and 30+ export markets.
Ownership category
akta.pro rank

Ferozsons Laboratories industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Generic medicines
  • Biotechnology products
  • Medical device distribution
  • Hepatitis treatments

Where Ferozsons Laboratories is headquartered

Location

Headquarters

HQ city
Lahore
HQ country
Pakistan
HQ region
Asia

Offices3 records

Markets served

Ferozsons Laboratories business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Sales (Domestic): Sale of branded generic pharmaceutical products across multiple therapeutic areas including cardiology, hepatology, gastroenterology, oncology, antivirals, antibiotics, and diabetes treatments. Net sales reached Rs.13,857.967 million in FY2025 with gross margin of 41.27%.
  2. Licensed Products (Gilead Partnership): Manufacturing and distribution of in-licensed products from Gilead Sciences including Sovaldi (sofosbuvir) for Hepatitis C, Remedia (remdesivir) for COVID-19, and Yeztugo (lenacapavir) for HIV prevention. Royalty-free voluntary licensing for 120 high-incidence countries.
  3. Contract Manufacturing: cGMP-compliant manufacturing services for international pharmaceutical companies. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble (Vicks VapoRub).
  4. Medical Devices Distribution: Distribution of advanced medical technologies including Boston Scientific interventional devices (cardiology, GI endoscopy, oncology, urology), Nihon Kohden patient monitoring and diagnostic systems, and Butterfly Network handheld ultrasound technology.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Ferozsons Laboratories product offering

Product offering

Core offering

Ferozsons Laboratories is a pharmaceutical manufacturer that develops, produces, and sells more than 140 branded generic medicines across therapeutic areas including oncology, cardiology, hepatology, gastroenterology, antidiabetics, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. The company also distributes advanced medical devices through global partnerships and operates cGMP-compliant contract manufacturing services for international pharmaceutical clients. Its subsidiary BF Biosciences manufactures biopharmaceuticals such as Sematide and Zeptide.

Product overview

Ferozsons Laboratories Limited operates as a patient-centric pharmaceutical company offering a broad portfolio of more than 140 pharmaceutical products across 12+ therapeutic areas (oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief). The company operates through two divisions: Pharmaceuticals (branded generics and in-licensed products) and Medical Technologies (distribution of advanced medical devices through global partnerships). Key pharmaceutical brands include Sovaldi (Hepatitis C), Remedia (COVID-19), and DiaresQ (childhood diarrhea). Subsidiary BF Biosciences Limited focuses on biopharmaceuticals including Zeptide (Tirzepatide) and Sematide (Semaglutide) for diabetes and obesity. Medical Technologies division distributes Boston Scientific interventional devices, Nihon Kohden diagnostic/monitoring systems, and Butterfly Network handheld ultrasound devices. The company also offers cGMP-compliant contract manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

  • Remedia: Remdesivir product launched for COVID-19 treatment under voluntary licensing partnership with Gilead
  • Zeptide
  • Sematide
  • Sovaldi

Products and services

  • Zeptide (Tirzepatide) An innovative tirzepatide treatment for Type 2 diabetes and obesity, manufactured and launched in Pakistan by BF Biosciences Limited (Ferozsons' biopharmaceutical joint venture with Bagó Group of Argentina). Targeted at patients needing advanced metabolic disease therapy.
  • Sematide (Semaglutide) Pakistan's first locally manufactured GLP-1 semaglutide therapy for diabetes, produced by BF Biosciences Limited. Targeted at patients requiring advanced GLP-1 therapy in Pakistan.
  • Remedia (Remdesivir) Remdesivir COVID-19 treatment manufactured under voluntary licensing partnership with Gilead Sciences for severe COVID-19 in hospitalized patients, also exported internationally.
  • Sovaldi (sofosbuvir) Sofosbuvir breakthrough direct-acting antiviral therapy for Hepatitis C introduced in Pakistan under a dedicated patient access program through partnership with Gilead Sciences.
  • DiaresQ Innovative nutritional product for childhood diarrhea, exclusively marketed in Pakistan through partnership with PanTheryx Inc., USA. Targeted at pediatric patients and caregivers.
  • Branded Generic Pharmaceutical Portfolio (140+ products) Broad portfolio of more than 140 branded generic pharmaceutical products covering oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. Targeted at healthcare providers and patients across Pakistan and 30+ export markets.
  • Farapulse PFA System Pulsed Field Ablation system developed by Boston Scientific for treatment of atrial fibrillation, introduced in Pakistan through Ferozsons' distribution partnership. Targeted at cardiology departments and electrophysiologists treating atrial fibrillation.
  • Boston Scientific Medical Devices Distribution Authorized distribution in Pakistan of Boston Scientific interventional medical devices across cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Targeted at Pakistani healthcare providers and hospitals.
  • Nihon Kohden Medical Technologies Distribution Authorized distribution in Pakistan of Nihon Kohden advanced diagnostic and patient monitoring systems including patient monitoring, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring. Targeted at Pakistani hospitals.
  • Butterfly Network Handheld Ultrasound Distribution Authorized distribution in Pakistan of Butterfly Network handheld ultrasound technology and AI-enabled digital medical imaging solutions with applications in emergency medicine, critical care, obstetrics, and primary care. Targeted at Pakistani healthcare providers.
  • Contract Manufacturing Services cGMP-compliant pharmaceutical manufacturing services with capacity for tablets (550M annually), capsules (222M), dry suspensions (2.5M bottles), ointments/creams (11M tubes), sachets (11M), ampoules, vials, pre-filled syringes, and lyophilized products. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble. Targeted at international pharmaceutical and consumer health companies outsourcing production.

Quantifiable outcome

  • Over 250,000 hepatitis C patients cured nationwide through Sovaldi access program
  • +3 more outcomes

Companies that use Ferozsons Laboratories

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Ferozsons Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ferozsons Laboratories partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, supporting and flagship.

  • Nihon KohdencoreChannel Partner/ Reseller/ Distributor · 1 January 2022Distribution partnership for advanced diagnostic and patient monitoring systems. Technologies include patient monitoring systems, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring technologies for hospitals and healthcare facilities across Pakistan.
  • PanTheryxsupportingChannel Partner/ Reseller/ Distributor · 1 January 2017Exclusive marketing partnership for DiaresQ, an innovative nutritional product for childhood diarrhea. Product recognized in Innovations 2030 Countdown Report by PATH, USAID, and NORAD.
  • GE HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 January 2016Channel partnership for marketing and sale of value-segment medical devices in Pakistan, expanding medical technology portfolio beyond pharmaceutical products.
  • BioGaiasupportingChannel Partner/ Reseller/ Distributor · 1 January 2012Partnership to introduce world's leading premium Swedish probiotics in Pakistan, expanding product portfolio in nutritional and digestive health category.
  • Boston ScientificcoreChannel Partner/ Reseller/ Distributor · 1 January 2008Authorized distributor in Pakistan for Boston Scientific medical devices since 2008. Partnership covers advanced interventional technologies in cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Ferozsons introduced Pakistan's first public-sector Pulsed Field Ablation programme at PIMS using the Farapulse PFA System.
  • Bagó GroupflagshipStrategic or Co-development Partner · 1 January 2006Joint venture established in 2006 to create BF Biosciences Limited, Pakistan's first biopharmaceutical company. cGMP-compliant biotechnology facility dedicated to manufacture of biological products. BF Biosciences successfully listed on PSX in 2024 following IPO. Strategic partnership also includes import and marketing of biological products in oncology and liver disease.
  • Curatis Pharma GmbHsupportingChannel Partner/ Reseller/ Distributor · 1 January 2002Strategic partnership for import and marketing of biological products in oncology and liver disease from Germany.
  • Gilead SciencesflagshipStrategic or Co-development PartnerRoyalty-free voluntary licensing partnership for manufacture and distribution of lenacapavir (HIV PrEP), sofosbuvir/Sovaldi (Hepatitis C), and remdesivir/Remedia (COVID-19) in 120 high-incidence resource-limited countries. Ferozsons is one of six generic partners including Dr. Reddy's, Emcure, Eva Pharma, Hetero, and Mylan. The partnership enabled introduction of breakthrough therapies in Pakistan including first direct-acting antiviral for Hepatitis C.
  • Butterfly NetworkcoreChannel Partner/ Reseller/ DistributorAuthorized distributor in Pakistan for Butterfly Network handheld ultrasound technology and digital medical imaging. Enables introduction of AI-enabled portable ultrasound solutions to healthcare providers across Pakistan with applications in emergency medicine, critical care, obstetrics, and primary care.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Ferozsons Laboratories competitors and assessment

Company assessment

Emerging players

  • Dr. Reddy's Laboratories: Indian-headquartered global generic and biopharmaceutical company with a similar voluntary licensing-led model for breakthrough antivirals (also a Gilead licensee). Comparable in licensed generics strategy, biopharma ambitions, and emerging markets export focus.
  • Hetero Labs: Indian-headquartered global generics manufacturer and one of the six Gilead voluntary licensees for Sovaldi, Remdesivir, and lenacapavir. Directly comparable in licensed antiviral manufacturing model and emerging markets supply footprint.

Direct peers

  • Searle Pakistan: Listed Pakistani pharmaceutical company offering branded generics and licensed products across similar therapeutic categories. Directly comparable in business model, regulatory standing, and Pakistan Stock Exchange listing.
  • Hilton Pharma: Karachi-based Pakistani pharmaceutical manufacturer with a comparable branded generics and licensing-led business model. Closely comparable in product breadth, domestic sales motion, and therapeutic area coverage.
  • Sami Pharmaceuticals: Pakistani pharmaceutical company operating in branded generics across multiple therapeutic areas including cardiology and gastroenterology. Directly comparable mid-sized domestic peer.
  • Getz Pharma: One of Pakistan's largest domestic pharmaceutical manufacturers with a broad branded generics portfolio across multiple therapeutic areas. Highly comparable in product mix, domestic market positioning, and export ambitions to Ferozsons.

Broad incumbents

  • Abbott Laboratories Pakistan: Multinational pharmaceutical incumbent with established Pakistan presence across branded generics and nutrition. Comparable as a competitor in the same therapeutic categories, though with broader global portfolio backing.
  • Bayer Pakistan: Multinational pharmaceutical and consumer health incumbent with Pakistan operations spanning cardiology, women's health, and specialty. Comparable as an established incumbent with overlapping product categories.
  • GlaxoSmithKline Pakistan: Listed Pakistani subsidiary of GSK offering vaccines, specialty, and general medicines. Comparable as a broad incumbent competing for the same prescriber base and therapeutic franchises.

Regional players

  • CCL Pharmaceuticals: Pakistani pharmaceutical manufacturer with broad branded generics portfolio. Comparable mid-cap domestic peer with overlapping therapeutic categories and similar Pakistan PSX listing structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ferozsons Laboratories social profiles

Digital presence

Ferozsons Laboratories compliance and trust

Trust signal

Compliance7 records

Ferozsons Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ferozsons Laboratories leadership team

Management profile

Number of profiles

Profiles7 records

Ferozsons Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Ferozsons Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ferozsons Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ferozsons Laboratories

What does Ferozsons Laboratories do?

Ferozsons Laboratories is a pharmaceutical manufacturer that develops, produces, and sells more than 140 branded generic medicines across therapeutic areas including oncology, cardiology, hepatology, gastroenterology, antidiabetics, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. The company also distributes advanced medical devices through global partnerships and operates cGMP-compliant contract manufacturing services for international pharmaceutical clients. Its subsidiary BF Biosciences manufactures biopharmaceuticals such as Sematide and Zeptide.

Is Ferozsons Laboratories a public or private company?

Ferozsons Laboratories is a public company. It is classified as public and is currently operating.

When was Ferozsons Laboratories founded?

Ferozsons Laboratories was founded in 1954. It employs 1,001 to 5,000 people.

Where is Ferozsons Laboratories based?

Ferozsons Laboratories is headquartered in Lahore, Pakistan, in the Asia region.

How does Ferozsons Laboratories make money?

Four revenue lines are on record. Pharmaceutical Sales (Domestic) is the primary driver. The others are licensed Products (Gilead Partnership), contract Manufacturing and medical Devices Distribution.

Who are Ferozsons Laboratories's main competitors?

Emerging players on record are Dr. Reddy's Laboratories and Hetero Labs. Direct peers are Searle Pakistan, Hilton Pharma, Sami Pharmaceuticals and Getz Pharma. Broad incumbents are Abbott Laboratories Pakistan, Bayer Pakistan and GlaxoSmithKline Pakistan. CCL Pharmaceuticals is listed as a regional player.

Does Ferozsons Laboratories have an API?

No public API is recorded for Ferozsons Laboratories.

What industry is Ferozsons Laboratories in?

Ferozsons Laboratories's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerGilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories LimitedGilead Sciences expanded its royalty-free voluntary licensing agreements for lenacapavir to include once-yearly PrEP for 120 high-incidence countries. The six partners—Dr. Reddy's, Emcure, Eva Pharma, Ferozsons, Hetero, and Mylan—will support manufacturing readiness and technology transfer while the Phase 3 PURPOSE 365 trial is ongoing.Business RecorderFerozsons Laboratories LimitedFerozsons Laboratories Limited reported a 9% increase in net sales to Rs.13,857.967 million and a 32% improvement in net profit to Rs.528.243 million in fiscal year 2025, following strong recovery from the 2023 trough when net profit fell to Rs.189.043 million. The company's shift toward in-market generic sales has improved margins, with gross margin recovering to 41.27% in 2025, while institutional sales declined 13% due to margin pressure. In the nine-month period of FY26, FEROZ posted 10.52% sales growth and 29% higher net profit of Rs.503.87 million, though export sales were impacted by Pak-Afghan border closure in Q3.TechJuiceAmerican Farapulse Heart Tech Debuts at PIMS to Treat Atrial FibrillationPakistan launched its first public-sector Pulsed Field Ablation programme at PIMS in Islamabad, utilizing the Farapulse PFA System developed by American company Boston Scientific and introduced locally by Ferozsons Laboratories Limited. The government constructed the upgraded PIMS Cardiac Centre at a cost of PKR 7.2 billion with an additional PKR 900 million for upgrades, with eligible heart patients to receive the advanced treatment free of charge. Four patients successfully underwent the procedure during the launch, with experts noting success rates approaching 99 percent in appropriately selected patients.BenzingaGilead Shares Drop As It Agrees To 'Royalty-Free' Coronavirus Drug Licence With Generic Drugmakers In 127Gilead Sciences signed voluntary licensing agreements with five generic drugmakers—Cipla Ltd., Hetero Labs Ltd., Jubilant Lifesciences, Ferozsons Laboratories, and Myla—to manufacture and supply Remdesivir in 127 countries, primarily low- to middle-income nations. The agreements are royalty-free until the WHO declares the pandemic over or an alternative treatment is approved, and the generic manufacturers will set their own pricing. Gilead shares closed 3.53% lower at $77.95 on Tuesday, reflecting investor concern over reduced exclusivity and revenue potential from the arrangement.